Targeting Thyroid Cancer PowerPoint Presentation

Slide 1 -

Targeting Thyroid Cancer

Slide 2 -

Program Goal

Slide 3 -

Thyroid Cancer Newly Detected 2013 (n=60,220)

Slide 4 -

Follicular Cell Thyroid Cancer Deaths 2013 (n = 1850)

Slide 5 -

Familial Syndromes

Slide 6 -

Thyroid Cancer Treatment “Pyramid”

Slide 7 -

Risk Stratification

Slide 8 -

ppt slide no 8 content not found

Slide 9 -

ppt slide no 9 content not found

Slide 10 -

RAI-Refractory Disease

Slide 11 -

Doxorubicin: Single-agent Activity

Slide 12 -

Doxorubicin +/- Cisplatin

Slide 13 -

Doxorubicin +/- Cisplatin: Results

Slide 14 -

ppt slide no 14 content not found

Slide 15 -

Targets in Thyroid Cancer

Slide 16 -

VEGF and Thyroid Cancer

Slide 17 -

Sorafenib

Slide 18 -

Sorafenib University of Pennsylvania

Slide 19 -

Sorafenib Results University of Pennsylvania

Slide 20 -

Sorafenib Ohio State

Slide 21 -

Sorafenib Results Ohio State

Slide 22 -

Sorafenib Response Rates Ohio State vs Penn

Slide 23 -

DECISION Study

Slide 24 -

DECISION Study Results

Slide 25 -

DECISION Study Response Rates

Slide 26 -

Lenvatinib (E7080) Background

Slide 27 -

Lenvatinib Response Rate

Slide 28 -

Differentiated Thyroid Cancers Phase 2 Studies -- Multitargeted TKIs

Slide 29 -

Summary of Angiogenesis Inhibition

Slide 30 -

Genetic Alterations in Thyroid Cancer

Slide 31 -

Concordance of Genetic Alterations in MAPK but Not PI3K Pathway Oncogenes

Slide 32 -

Selumetinib (AZD6244)

Slide 33 -

Selumetinib Response Rate

Slide 34 -

ppt slide no 34 content not found

Slide 35 -

Impact of Selumetinib on 124I Incorporation

Slide 36 -

ppt slide no 36 content not found

Slide 37 -

Responses for RAI-Treated Patients

Slide 38 -

BRAF

Slide 39 -

Vemurafenib

Slide 40 -

Vemurafenib Response Rate

Slide 41 -

Current Studies for BRAF Mutant Thyroid Cancer

Slide 42 -

Summary of BRAF and MEK targets

Slide 43 -

Medullary Thyroid Cancer

Slide 44 -

Presentations of MCT

Slide 45 -

MTC: Hereditary vs Sporadic?

Slide 46 -

Hereditary MTC Until Proven Otherwise

Slide 47 -

Sporadic MTC Frequency of RET Mutations

Slide 48 -

Vandetanib (ZD6474)

Slide 49 -

Vandetanib: Randomized Phase 3 Trial

Slide 50 -

Vandetanib: PFS

Slide 51 -

Vandetanib: Objective Tumor Assessments

Slide 52 -

Cabozantinib (XL184)

Slide 53 -

Cabozantinib: Phase 3 Study Design (EXAM)

Slide 54 -

Cabozantinib: PFS

Slide 55 -

Summary of Medullary Thyroid Cancer

Slide 56 -

Abbreviations

Slide 57 -

Abbreviations (cont)

Slide 58 -

Abbreviations (cont)

Slide 59 -

References

Slide 60 -

References (cont)

Slide 61 -

References (cont)

Slide 62 -

References (cont)

Slide 63 -

References (cont)

Slide 64 -

References (cont)

Slide 65 -

References (cont)